Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Randomized phase 2 study of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus FOLFIRI/FOLFOX and bevacizumab as second-line treatment of advanced colorectal cancer (DeFianCe).
Authors
Zev A. Wainberg
UCLA Medical Center, Los Angeles, CA;
Zev A. Wainberg , Ralph V. Boccia , John H Strickler , Markus H. Moehler , Cynthia A. Sirard , Erin K Walsh , Elizabeth C Parker , Keun-Wook Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05480306
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS275)
DOI
10.1200/JCO.2023.41.4_suppl.TPS275
Abstract #
TPS275
Poster Bd #
P17
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
DKN-01 plus bevacizumab and chemotherapy as second-line (2L) investigational therapy in advanced microsatellite stable (MSS) colorectal adenocarcinoma (CRC): DeFianCe trial.
First Author: Meredith Pelster
Poster
2023 ASCO Annual Meeting
A phase Ib/II study to evaluate surufatinib combined with camrelizumab and chemotherapy in the second-line treatment of advanced colorectal cancer: Phase Ib results.
First Author: Sheng Li
Poster
2013 Gastrointestinal Cancers Symposium
Phase II trial of irinotecan, S-1, and bevacizumab (IRIS/Bev) combination chemotherapy as second line for advanced colorectal cancer (NCCSG04).
First Author: Yasumasa Takii
Poster
2012 Gastrointestinal Cancers Symposium
Phase II study alternating mFOLFOX 6 and FOLFIRI (FIREFOX) plus bevacizumab (bev) regimen in first-line treatment of advanced colorectal cancer in Japanese patients (KSCC 0801).
First Author: Yutaka Ogata